Market Overview

Newron Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

Share:

Newron
Pharmaceuticals S.p.A.
("Newron") (SIX: NWRN), a biopharmaceutical
company focused on the development of novel therapies for patients with
diseases of the central and peripheral nervous system, today announced
that Stefan Weber, CEO, will present at the Wedbush PacGrow Healthcare
Conference in New York, NY, on Wednesday, August 15, 2018 at 1:20 p.m.
ET.

About Newron Pharmaceuticals
Newron (SIX: NWRN) is a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central and peripheral nervous system.
The Company is headquartered in Bresso near Milan, Italy. Xadago®
(safinamide) has received marketing authorization for the treatment of
Parkinson's disease in the European Union, Switzerland and the USA, and
is commercialized by Newron's Partner Zambon. US WorldMeds holds the
commercialization rights in the USA. Meiji Seika has the rights to
develop and commercialize the compound in Japan and other key Asian
territories. In addition to Xadago® for Parkinson's disease, Newron has
a strong pipeline of promising treatments for rare disease patients at
various stages of clinical development, including sarizotan for patients
with Rett syndrome and ralfinamide for patients with specific rare pain
indications. Newron is also developing Evenamide as the potential first
add-on therapy for the treatment of patients with positive symptoms of
schizophrenia. For more information, please visit: www.newron.com

View Comments and Join the Discussion!